A patient in IN8bio's INB-200 clinical trial has now surpassed four years without progression, a significant clinical milestone in front-line, grade IV glioblastoma (GBM), demonstrating the potential ...

DALLAS, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc. ® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the ...

Rossell Techsys Limited ( (IN:ROSSTECH) ) just unveiled an announcement. Rossell Techsys Limited has released its investor presentation for the quarter ending June 30, 2025, detailing the company’s ...

RICHMOND, Calif.-- (BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and first quarter 2025 financial results.

Detailed price information for Gxo Logistics Inc (GXO-N) from The Globe and Mail including charting and trades.

First Quarter 2025 Financial Highlights Cash Position: Cash and cash equivalents, and short-term investments of $136.5 million as of March 31, 2025, compared with $147.3 million as of December 31 ...

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines ...

Commonwealth Bank of Australia ( ($AU:CBA) ) just unveiled an announcement. The Commonwealth Bank of Australia has released a presentation aimed ...

Poster Presentation #21 (Abstract #11538): Personalized Radiation Strategies in Soft Tissue Sarcoma Title: MicroRNA-based Biomarkers of Outcome in Soft Tissue Sarcoma Treated with Hypofractionated ...

Announced CNSide® CSF assay platform launch timeline Initiated the REYOBIQ dose optimization trial for patients with ...

Upcoming oral presentation: "INB-200: Phase 1 Study of Gene-Modified Autologous Gamma-Delta (γδ) T Cells in Newly Diagnosed Glioblastoma Multiforme (GBM) Patients Receiving Maintenance ...

C4T had a productive Type C meeting with the U.S. Food and Drug Administration (FDA) that enabled further refinement of the cemsidomide registrational development plan. By year-end 2025, C4T expects ...